(Q36262215)

13 August 2017

1 reference

title

Optimizing therapy for myeloid disorders of Down syndrome (English)

1 reference

13 August 2017

David K H Webb

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

British Journal of Haematology

13 August 2017

published in

1 reference

13 August 2017

volume

131

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

3-7

1 reference

Natural history of GATA1 mutations in Down syndrome

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Onco

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Down syndrome, drug metabolism and chromosome 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05700.X

10.1111/J.1365-2141.2005.05700.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference